Urethral Stricture Treatment by Hybrid Cell Therapy, Granted Japanese Patent
2.7.2020 09:00:00 EEST | Business Wire | Press release
Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to patients who had recurrence of the disease after earlier conventional treatments, has been reported by this method called “Bees-Haus” (Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture; https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701006026/en/
Biomaterial research facility of JBM in Tokyo, where improvised scaffolds for regenerative medicine applications like Bees-haus, implants and medical devices are developed. (Photo: Business Wire)
Male urethra, a tubular passage to let the urine out from urinary bladder, when affected with narrowing or stricture of the lumen, causes difficulty in voiding urine, urinary retention, and pain during micturition. Treatments include dilatation with balloon or urethrotomy under endoscopy at early stages and surgical urethroplasty under general anesthesia using patient’s autologous oral/buccal tissue graft in severe disease or long segment stricture. After surgery, for a while, patients pass urine through catheter drainage and complications such as stricture recurrence, urinary tract infection, impotence, sexual dysfunction, and incontinence, have been reported (Gallegos & Santucci F1000Res. 2016;5-2913 & Barbagli et al. European Urology Supplements 2016;15-1).
Bees-Haus method of cell therapy could be performed in two-steps, both as day care procedure. A small bit of patient’s oral tissue is taken, cells cultured in lab, and transplanted through endoscopy. Very simple and convenient for urologist and relatively painless to patients with shorter hospital stay reducing healthcare cost and burden, because of lesser complications, making Bees-Haus easy to adopt. A larger multicentric study is under proposal by JBM Inc, to validate its efficacy to make this a routine procedure to benefit many patients with better quality of life.
Urethral stricture disease occurs mainly in men and its incidence climbs sharply after 55 years in western population. An estimated 0.6% in susceptible populations are affected in which 4% of male patients require interventional procedure. Annually 200 million USD is spent in USA for urethral stricture treatment, which doesn’t include cost of medication. The Americas hold the largest share in the global urethral stricture market, followed by Europe and Asia Pacific. JBM has applied for patents worldwide including USA, EU, United Kingdom and are looking for country-wise partners for technology licensing out. JBM also established a biomaterial laboratory to develop novel scaffolds for various applications in regenerative medicine, implants, and medical devices in Tokyo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701006026/en/
Contact information
Queries to:
GN Corporation Ltd.
Samuel JK Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Visa Research Finds Consumer Trust is Accelerating the Path to Agentic Commerce9.9.2026 14:00:00 EEST | Press release
Visa (NYSE: V) today announced the Visa Trust Index for agentic commerce, providing new insight into how consumers are navigating the next evolution of AI shopping and payments. While consumers are increasingly using AI across the shopping journey, only 23% of U.S. consumers trust GenAI to handle payment transactions on their behalf. However, confidence in agentic commerce shifts when payments brands come into consideration. Visa emerged as the most trusted brand for AI-powered payments with 61% of respondents saying they would trust Visa to handle agentic transactions. The findings suggest that while consumers are intrigued by agentic commerce, trust remains the key factor determining whether adoption moves from possibility to reality. "AI has the potential to fundamentally reshape how people discover, buy and pay for goods and services, much like e-commerce and mobile commerce did before it," said Oliver Jenkyn, Group President, Visa. "While we're still in the early days, trust will
NIQ’s Optiq™ Goes Live in Discover, Expanding Access to Trusted Consumer Intelligence9.9.2026 13:45:00 EEST | Press release
NielsenIQ (NIQ), a leading consumer intelligence company, today announced that Optiq is now live within Discover, NIQ’s platform for accessing, analyzing and applying consumer and market intelligence, advancing the company’s strategy to make trusted consumer intelligence easier to access and apply. Where Ask Arthur introduced new ways to explore and analyze NIQ data through AI within Discover, Optiq expands that experience across conversational AI, mobile access and enterprise AI integrations, giving clients greater flexibility to access and apply NIQ intelligence across the applications and workflows where they make decisions. “AI models are becoming ubiquitous. Trusted intelligence is not,” said Irina Stoian, Chief AI Commercial Officer at NIQ. “That is why we are building the full system. Think of it like a body: harmonized NIQ data acts as the nervous system, delivering signals about the marketplace to decisioning agents that act as the brain, helping clients evaluate relevant info
Cegid and Silae Join Forces to Create a European Leader in AI-Driven Business Technology9.9.2026 13:32:00 EEST | Press release
Cegid, an AI-driven European leader in cloud business management software for small and medium-sized businesses (SMBs), and accounting professionals, and Silae, France’s leading payroll and human resources platform, today announced their intention to merge. The combination will create a national technology champion and the leading European technology platform for businesses and their partners, helping them grow safely and efficiently with the support of a fully integrated and compliant suite covering their end-to-end financial and administrative needs. Between them, Cegid, following its recent acquisition of Shine, and Silae power the day-to-day accounting, tax, finance and payroll of 2 million end-customers and more than 15,000 chartered accountancy firms, while producing more than 13 million payslips across Europe every month. The planned transaction is expected to value the combined group at more than €10 billion in enterprise value, positioning it as one of France's largest softwar
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year9.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which further support COMP360’s differentiated profile and potential for long lasting benefit. The open-label Part C data demonstrate four important findings: first, notable additional benefit was observed with an added reduction in MADRSscore leading to an average 13-point reduction from baseline at Week 52 and extended out to 1 year for participants who were randomized to the 25 mg arm and received an additional dosein Part C; second, for participants in the Placebo arm who received their first dose of COMP360 25 mg in Part C, these findings further reinforce that a single dose of 25 mg has the potential to produce rapid onset, meaningful effect and durabi
New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems9.9.2026 12:42:00 EEST | Press release
ABB today published a new report, The Strategic Case for Hybrid AC/DC Power: Shaping the Transition to the Next Electrical Architecture, developed in collaboration with Boston Consulting Group (BCG). The report makes the case that direct current (DC) technology is moving from the periphery to the center of industrial, commercial, and digital infrastructure – and that the decisions made by business leaders and policymakers in the next two to three years will determine who shapes that transition and who inherits it. The future of power distribution is not an either-or choice between alternating current (AC) and direct current, but a hybrid system that combines the strengths of both technologies. While AC will remain the backbone of most transmission and regional distribution networks, DC is expected to play an increasingly important role within facilities where many major energy sources and loads already operate natively on direct current. The fastest-growing technologies, including sola
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom